GILD vs PLUS · P/E 18, rev $29.44B vs P/E 17, rev $2.07B
Gilead Sciences Inc (GILD) versus ePlus inc (PLUS) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Not investment advice. Open the GILD and PLUS stock pages for the full models.
Not investment advice.